In-Practice Evaluation of Atacand 16mg Antihypertensive Effect

This study is currently recruiting participants.

Verified by AstraZeneca, January 2009

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00802542

Purpose

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Condition
Essential Hypertension

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Candesartan cilexetil CV 11974

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	In-Practice Evaluation of Atacand 16mg Antihypertensive Effect

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Decrease in blood pressure [ Time Frame: once after 4 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	400
Study Start Date:	November 2008
Estimated Study Completion Date:	February 2009

Groups/Cohorts
1 Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

out-patient departments

Criteria

Inclusion Criteria:

Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decid
Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria:

Hypersensitivity to the active substance or to any of the excipients of Atacand.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00802542

Contacts

Contact: AstraZeneca Latvia Clinical Study Information

+371 67377100

agrita.hartmane@astrazeneca.com

Locations

Latvia
Research Site	Recruiting
Riga, Latvia
Research site	Not yet recruiting
Liepaja, Latvia
Research site	Not yet recruiting
Daugavpils, Latvia
Research site	Not yet recruiting
Jelgava, Latvia

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Agrita Hartmane

AstraZeneca

More Information

Responsible Party:	AstraZeneca MC Latvia ( Janis Dobelis )
Study ID Numbers:	NIS-CLV-ATA-2008/1
Study First Received:	December 4, 2008
Last Updated:	January 12, 2009
ClinicalTrials.gov Identifier:	NCT00802542
Health Authority:	Latvia: State Agency of Medicines

Keywords provided by AstraZeneca:

Hypertension
blood pressure
Atacand

Study placed in the following topic categories:

Candesartan cilexetil
Candesartan
Vascular Diseases

Essential hypertension
Angiotensin II
Hypertension

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Cardiovascular Diseases

Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009